Horse tranquilliser trial is awarded $750,000 grant for Parkinson’s research

News

Author: Simge Eva DoganPublished: 26 July 2018

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

ketamine

Researchers at the University of Arizona College of Medicine, Tucson, US, will be trialling ketamine – a recreational drug previously used to medicate people with depression – as a treatment for Parkinson’s.

The research – led by Dr Scott Sherman – is being supported with a three-year grant of $750,000 from the Arizona Biomedical Research Commission.

The initial clinical trial will test the effect of ketamine for treating dyskinesia in 10 patients. In addition, the researchers will carry out a separate rodent study to examine how the drug affects the brain.

Dr Scott Sherman, a neurologist at the University of Arizona College of Medicine, said: “Ketamine has been long overlooked. Now it could prove very useful for Parkinson’s patients.”

For information on the latest Parkinson’s research please visit the European Parkinson’s Disease Association website.

For more information on this article click here.

Go Back

Share this story

Comments


Related articles


A scene from a Parkinson's video game

Resources & Tools

How video games can combat “unmet needs” in Parkinson’s

We hear from research assistant Dr Sofia Balula Dias from Portugal on a Eur

READ MORE
Parkinson's in the news

Global update

Parkinson’s in the news: March

A roundup of Parkinson’s news stories in March

READ MORE
Webinar pain and fatigue

PD in Practice

WEBINAR: Get expert advice on managing Parkinson’s pain and fatigue

Join this free MJ Fox Foundation live webinar

READ MORE